However, the selective TAAR1 agonist RO5166017 has been reported to impact pre- (glutamate release) and post-synaptic (phosphorylation of AMPA receptors) glutamatergic neurotransmission in the striatum of a Parkinson’s disease mouse model [35]. Here, TAAR1 is linked to Parkinson disease.